In a nutshell This trial is examining the effectiveness of radical prostatectomy, in newly diagnosed advanced prostate cancer. The main outcome to be measured will be survival without the cancer worsening. This trial is recruiting in the United States. The details Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy (ADT) may...
Read More
In a nutshell This study investigated the effectiveness of a radionuclide (RN), [¹??Lu]-PSMA-617, to treat metastatic castration-resistant prostate cancer (mCRPC) that has worsened after standard treatments. They found that this treatment was safe and effective for these patients. Some background Prostate cancer (PC) affects the...
Read MoreIn a nutshell This phase 3 trial will evaluate the safety and effectiveness of olaparib (Lynparza) and abiraterone (Zytiga) combination in prostate cancer. The main outcome will be the rate of survival without cancer growing or spreading. The details Prostate cancer (PC) is cancer that originates in the prostate gland. When cancer progresses to a...
Read More
In a nutshell This trial evaluates the effectiveness of using chemotherapy in combination with radium-223 (a type of internal radiotherapy). The main outcome to be measured is overall survival. This trial is taking place in the United States. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...
Read More
In a nutshell This study evaluates the effectiveness of medication and focal radiation in the treatment of prostate cancer resistant male hormone suppression. The main outcome to be measured in this trial is the number of patients whose cancer does not grow or spread and who are alive at 18 months after treatment. This trial is taking place in Ann...
Read More
In a nutshell This trial is comparing drug therapy and drug therapy with prostate surgery or radiation for the treatment of advanced prostate cancer. The main outcome to be measured is overall survival. This trial is recruiting in Houston (Texas), USA. The details Prostate cancer can be treated by medication, surgery or...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic ablative body radiotherapy (SABR) used as a treatment in low volume metastatic (spread) prostate cancer. This study found that SABR is effective and has few side-effects. Some background Stereotactic ablative body radiotherapy (SABR) is a treatment option...
Read More
In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...
Read More
In a nutshell This study aimed to evaluate the usefulness of transurethral resection of the prostate (TURP). This study found that TURP is a surgical option to relieve bladder obstruction in patients with locally advanced prostate cancer. Some background Advanced prostate cancer may cause significant complications which affect...
Read More
In a nutshell This study aimed to compare quality of life between patients with metastatic prostate cancer who were treated with androgen deprivation therapy (ADT) and docetaxel and those who were treated with ADT alone. This study found that ADT and docetaxel was associated with statistically worse QOL at 3 months. However, QOL was better...
Read More
In a nutshell This study aimed to discover if docetaxel (Taxotere) added to androgen-deprivation therapy (ADT) increases overall survival for patients with metastatic hormone-sensitive prostate cancer. This study found that overall survival was higher for patients who received ADT and docetaxel compared to those who took ADT. Some...
Read MoreIn a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...
Read More
